



The brand behind brands

Dixon Technologies (India) Limited

13th May, 2026

To Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 540699 ISIN: INE935N01020	Scrip Code- DIXON ISIN: INE935N01020

Dear Sir/Madam,

Sub: Submission of copies of newspaper publication under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of extracts of Audited Standalone and Consolidated Financial Results for the Quarter and Financial year ended 31st March, 2026 published in the following newspapers on 13th May, 2026:

1. Business Standard- English
2. Business Standard- Hindi

We request you to kindly take this on your record.

Thanking You,

For DIXON TECHNOLOGIES (INDIA) LIMITED

Ashish Kumar
President- Chief Legal Counsel & Group Company Secretary

Encl: as above

निम्नलिखित संपत्ति यानी मकान/प्लॉट सं. 1017, पहली मंजिल, निर्वाण ग्रीन्स-4, (13.02 वर्ग मज), जो खेवट/खाली सं. 139/142 और 145/148 में शामिल है; खसरा नंबर 1246/303/2(0-8), 310/1(0-16), 1245/302(2-8), 1246/303/1(2-0), 311/2(0-7), 310/2/2(0-8), 310/2/1(3-14), 311/1(4-9) किते 8; कुल रकमा 14 बीघा 8 बिसवा में से 0 बीघा 0-1/4 बिसवा का 13/14400 हिस्सा; इदबस्त सं. 183, रकमा खासपुर, तहसील खार, जिला एनएसईएल नगर (मोहाली) का सम्पूर्ण एवं सर्वांगीण हिस्सा, यह संपत्ति पंजीकृत मालिक श्रीमती नीता कश्यप पत्नी श्री संजीवी मुरली प्रसाद के नाम पर दस्तावेज सं. 2021-22/15/1/7931, दिनांक 08-सितंबर-2021 के अनुसार दर्ज है। चौहवी निम्नानुसार है: पूर्व: एनए, पश्चिम: एनए, उत्तर: एनए, दक्षिण: एनए।

इसलिए, सीधे संपर्क के बजाय यह सार्वजनिक सूचना जारी की जा रही है। कर्जदार(1) तथा/अथवा उनके गारंटर(1), जहां लागू हो, से अनुरोध किया जाता है कि वे इस सूचना के प्रकाशन की तारीख से 60 दिनों के भीतर बकाया राशि जमा कर दें। ऐसा न करने पर, 60 दिनों की अवधि समाप्त होने के बाद वित्तीय सम्पत्तियों के प्रतिभूतिकरण एवं पुनर्गठन तथा प्रतिभूति हित प्रवर्तन अधिनियम, 2002 की धारा 13 की उप-धारा (4) के तहत अनुमत आगे की कार्रवाई शुरू की जाएगी। कर्जदारों का ध्यान विशेष रूप से अधिनियम की धारा 13 की उप-धारा (8) की ओर आकर्षित किया जाता है, जिसमें प्रत्याभूत सम्पत्तियों को वापस पाने के उनके अधिकारों का उल्लेख है।

तारीख: 13.05.2026
स्थान: दिल्ली

हस्ता/- (अधिकृत अधिकारी)
एक्सिस बैंक लि.

कच्चा सूचना
(अचल संपत्ति हेतु)

जबकि,

सीएफएम एसेट रिकंस्ट्रक्शन प्राइवेट लिमिटेड (यहाँ आगे 'सीएफएमएआरसी' कहा गया है) (सीआईएन: U67100GJ2015PTC083994), एक विधिवत पंजीकृत एसेट रिकंस्ट्रक्शन कंपनी, के अधोहस्ताक्षरी प्राधिकृत अधिकारी ने वित्तीय आस्तियों के प्रतिभूतिकरण और पुनर्निर्माण तथा प्रतिभूति हित प्रवर्तन अधिनियम, 2002 (सरफासी अधिनियम) के तहत और प्रतिभूति हित (प्रवर्तन) नियमावली, 2002 के संबंधित नियमों के साथ पठित धारा 13(12) के तहत प्रदत्त निम्नलिखित नोटिस जारी करता है:

सम्मान कैपिटल लिमिटेड (पूर्ववर्ती इंडिया बुल्स हाउसिंग फाइनेंस लिमिटेड (आईएचएफएल)) (अब सम्मान कैपिटल लि. नाम से ज्ञात) के प्राधिकृत अधिकारी ने नियमावली के नियम 3 के साथ पठित सरफासी अधिनियम की धारा 13(12) के तहत प्रदत्त शक्तियों का प्रयोग कर मांग नोटिस दिनांकित 15.03.2023 जारी किया जिसमें कर्जदार(ओं) जयप्रकाश नारायण झा और शालिनी से नोटिस में उल्लिखित खाता सं. HHLDCP00131855 के तहत दिनांक दिनांक 10.03.2023 को राशि रु. 9,75,879.55/- (रुपये नौ लाख पचहत्तर हजार आठ सौ उनहासी और पचपन पैसा मात्र) को इस पर लागू ब्याज और अन्य प्रभारों सहित उक्त नोटिस की प्राप्ति की तारीख से 60 दिनों के अंदर अदा करने के लिए कहा।

आईएचएफएल ने असाइनमेंट एग्रीमेंट दिनांक 27.12.2019 के माध्यम से उपरोक्त ऋण खाते के अपने सभी अधिकारों, हक और हित को इंडियन बैंक के पक्ष में सौंप दिया। इसके आगे इंडियन बैंक ने असाइनमेंट एग्रीमेंट दिनांक 20.12.2023 के अनुसार उपरोक्त ऋण खाते के अपने सभी अधिकारों, हक और हित को सीएफएमएआरसी ट्रस्ट-133 के ट्रस्टी के पक्ष में सौंप दिया, जिसके अनुसार सीएफएमएआरसी ने उपरोक्त ऋण खाता संख्या के संबंध में एक प्रत्याभूत ऋणदाता की भूमिका में आ गया है।

कर्जदार(ओं) द्वारा राशि चुकता करने में असमर्थ रहने पर एतद्वारा कर्जदार(ओं) और सर्व साधारण को सूचित किया जाता है कि अधोहस्ताक्षरी ने प्रतिभूति हित (प्रवर्तन) नियमावली, 2002 के नियम 8 के साथ पठित उक्त अधिनियम की धारा 13 की उप-धारा(4) के तहत प्रदत्त शक्तियों का प्रयोग कर यहाँ नीचे वर्णित संपत्ति का 08.05.2026 को कच्चा ले लिया है। विशेष रूप से कर्जदार(ओं) और सामान्य रूप में सर्व जन को संपत्ति से कोई लेन-देन न करने के लिए आग्रह किया जाता है तथा संपत्ति के साथ कोई भी लेन-देन दिनांक 10.03.2023 को राशि रु. 9,75,879.55/- (रुपये नौ लाख पचहत्तर हजार आठ सौ उनहासी और पचपन पैसा मात्र) और इस पर आगे की ब्याज, अन्य प्रभारों के लिए सीएफएमएआरसी के प्रभार के अधीन होगा।

प्रत्याभूत परिसंपत्ति को मुक्त कराने के लिए उपलब्ध समय में अधिनियम की धारा 13 की उप-धारा (8) के प्रावधानों में कर्जदार का ध्यान आकृष्ट किया जाता है।

अचल संपत्ति का विवरण

प्लॉट नं. L@E-501, सुपर एरिया 965 वर्ग फीट, 5वीं मंजिल, टॉवर-ई लक्जुरिया एस्टेट में, आदित्य वर्ल्ड सिटी, ऑफ एनएच-24, सेक्टर-6, गाजियाबाद-201010, उत्तर प्रदेश

स्थान: गाजियाबाद
दिनांक: 08.05.2026

हस्ता/- प्राधिकृत अधिकारी
सीएफएम एसेट रिकंस्ट्रक्शन प्राइवेट लिमिटेड
सीएफएमएआरसी ट्रस्ट-133 के ट्रस्टी की बनता से कार्यरत

DIXON TECHNOLOGIES (INDIA) LIMITED Dixon

Regd. Office : B-14 & 15, Phase-II, Noida, Gautam Budh Nagar, Uttar Pradesh- 201305
CIN: L32101UP1993PLC066581, Website: www.dixoninfo.com, Ph. No.: 0120 4737200

Extract Of Audited Financial Results For The Quarter and Year Ended March 31, 2026

Figure above depicts consolidated result Q4, FY25-26 in comparison with Q4, FY24-25

Extract of Audited Consolidated and Standalone Financial Results
for the Quarter & Year Ended March 31, 2026

(Rupees in Lakhs)

S. No.	Particulars	Standalone			Consolidated		
		Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
		31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-26	31-Mar-25	31-Mar-26
1	Total Income from Operations	94,261	112,681	473,246	1,059,481	1,030,382	4,958,584
2	Net Profit for the period before tax (before exceptional and extraordinary items)	8,702	7,730	88,817	36,976	32,566	207,056
3	Net Profit for the period before tax (after exceptional and extraordinary items)	8,702	32,767	88,817	36,976	57,603	207,056
4	Net profit for the period after tax (after exceptional and extraordinary items)	7,790	27,855	75,944	29,797	46,495	184,425
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	7,833	27,738	75,953	29,883	46,385	164,492
6	Equity Share Capital (Face value Rs. 2 each)	1,216	1,205	1,216	1,216	1,205	1,216
7	Reserves (excluding Revaluation Reserves) as shown in the Audited Balance Sheet of the previous year			322,685			466,451
8	Earnings per share (face value of Rs. 2/- per share) (not annualised)						
	Basic earnings per share (in rupees)	12.87	46.49	125.44	49.22	77.59	271.59
	Diluted earnings per share (in rupees)	12.76	45.78	124.41	48.81	76.42	269.35

Note:

- The above is an extract of the detailed format of Yearly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results is available on the Company's website (www.dixoninfo.com) under the head- Financial Performance-> Quarterly Results and on Stock Exchanges website (www.bseindia.com and www.nseindia.com). The said Financial results can also be accessed by scanning the Quick Response (QR) code as provided below.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 12, 2026.



On behalf of the Board
For Dixon Technologies (India) Limited
Sd/-
Atul B. Lal
Vice Chairman Cum Managing Director
(DIN: 00781436)

Place: New Delhi
Date: 12/May/2026

GLENN SALDANHA

India's pharmaceutical sector is entering a defining phase in its evolution. For decades, the country has been recognised globally for its scale, reliability and quality in supplying medicines to the world. The next chapter, however, is about moving beyond scale — towards science-led innovation, advanced manufacturing and globally integrated research ecosystems.

Enabling this transition requires regulatory systems that evolve alongside national ambition.

Over the past few years, India has begun demonstrating precisely that shift. A series of pragmatic reforms in the pharmaceutical regulatory framework signals a broader policy recognition that effective regulation becomes enabling infrastructure for growth, innovation and public health.

At the same time, regulators carry a complex responsibility of balancing innovation, patient safety and access at national scale. As the pharmaceutical sector grows in scientific depth and global reach, that balancing act becomes even more critical.

At the centre of this transition is the Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare. Through targeted policy measures, the regulator has begun aligning oversight more closely with risk and outcomes, maintaining rigour where patient safety demands it while simplifying processes where procedural requirements add limited public health value.

This is not deregulation — it is regulatory maturity.

Process density to policy precision

Highly regulated industries depend on clear rules, predictable timelines and consistent oversight. Yet, over time, regulatory systems can accumulate layers of procedure that outlive their original purpose. When that happens, compliance risks becoming process-heavy without necessarily improving safety outcomes.

The current reform trajectory reflects

tors to deploy attention where it matters most, while providing industry with the predictability required for long-cycle investments in research, manufacturing infrastructure and skilled talent.

Enabling research without compromising accountability

One of the most consequential reforms has been the rationalisation of the test licence framework governing research and development (R&D).

Historically, even small-scale non-commercial R&D manufacturing required prior regulatory approvals, often extending experimentation timelines unnecessarily. Recognising that early-stage research carries fundamentally different risk profiles from commercial manufacturing, the regulator has introduced mechanisms that allow companies to proceed through notification rather than prior permission in defined cases.

The change is subtle but significant. It reduces avoidable delays while retaining traceability and regulatory accountability.

For companies investing in scientific discovery, the concern is rarely regulation itself — it is unpredictability. Clear, proportionate frameworks provide confidence to invest in long-cycle research programmes — something India increasingly seeks to attract.

Strengthening export competitiveness

A similar philosophy underpins the simplification of procedures for certain bioavailability and bioequivalence (BA/BE) studies, particularly those undertaken for export markets.

These studies are globally standardised components of generic drug development. Aligning regulatory oversight with their actual risk profile enables faster execution without diluting scrutiny.

For India, one of the world's most important suppliers of affordable medicines, such efficiencies translate directly into stronger export competitiveness and responsiveness to global demand.

A RISK-BASED SYSTEM ALLOWS REGULATORS TO PAY ATTENTION WHERE IT MATTERS MOST, WHILE PROVIDING INDUSTRY WITH PREDICTABILITY.

DIXON TECHNOLOGIES (INDIA) LIMITED Dixon

Regd. Office : B-14 & 15, Phase-II, Noida, Gautam Budh Nagar, Uttar Pradesh- 201305
CIN: L32101UP1993PLC066581, Website: www.dixoninfo.com, Ph. No.: 0120 4737200

Extract Of Audited Financial Results For The Quarter and Year Ended March 31, 2026

Figure above depicts consolidated result Q4, FY25-26 in comparison with Q4, FY24-25

Extract of Audited Consolidated and Standalone Financial Results for the Quarter & Year Ended March 31, 2026

(Rupees in Lakhs)

S. No.	Particulars	Standalone			Consolidated		
		Quarter ended	Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
		31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-26	31-Mar-25	31-Mar-26
1	Total Income from Operations	94,261	112,681	473,246	1,059,481	1,030,382	4,958,584
2	Net Profit for the period before tax (before exceptional and extraordinary items)	8,702	7,730	88,817	36,976	32,566	207,056
3	Net Profit for the period before tax (after exceptional and extraordinary items)	8,702	32,767	88,817	36,976	57,603	207,056
4	Net profit for the period after tax (after exceptional and extraordinary items)	7,790	27,855	75,944	29,797	46,495	164,425
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	7,833	27,738	75,953	29,883	46,385	164,492
6	Equity Share Capital (Face value Rs. 2 each)	1,216	1,205	1,216	1,216	1,205	1,216
7	Reserves (excluding Revaluation Reserves) as shown in the Audited Balance Sheet of the previous year			322,685			466,451
8	Earnings per share (face value of Rs. 2/- per share) (not annualised)						
	Basic earnings per share (in rupees)	12.87	46.49	125.44	49.22	77.59	271.59
	Diluted earnings per share (in rupees)	12.76	45.78	124.41	48.81	76.42	269.35

Note:

- The above is an extract of the detailed format of Yearly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results is available on the Company's website (www.dixoninfo.com) under the head- Financial Performance-> Quarterly Results and on Stock Exchanges website (www.bseindia.com and www.nseindia.com). The said Financial results can also be accessed by scanning the Quick Response (QR) code as provided below.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 12, 2026.



Place: New Delhi
Date: 12/May/2026

On behalf of the Board
For Dixon Technologies (India) Limited
Sd/-
Atul. B. Lall
Vice Chairman Cum Managing Director
(DIN: 00781436)